Your session is about to expire
← Back to Search
Other
A Study of ZN-c3 in Participants With Solid Tumors
Phase 1
Recruiting
Research Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through completion, average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new drug called ZN-c3 on its own. It focuses on patients with specific advanced cancers that have DNA damage. The drug aims to stop cancer cell growth by targeting these damaged cells.
Eligible Conditions
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through completion, average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through completion, average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose Escalation
Dose Expansion
Secondary study objectives
Dose Escalation, Food Effect cohort & Dose Expansion
Dose Escalation, Food Effect cohort and Dose Expansion
Food Effect Cohort
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Single Agent Food Effect CohortExperimental Treatment1 Intervention
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
Group II: Single Agent Dose ExpansionExperimental Treatment1 Intervention
Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
Group III: Single Agent Dose EscalationExperimental Treatment1 Intervention
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
Find a Location
Who is running the clinical trial?
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncLead Sponsor
7 Previous Clinical Trials
635 Total Patients Enrolled
K-Group BetaLead Sponsor
5 Previous Clinical Trials
519 Total Patients Enrolled
Philippe Pultar, MDStudy DirectorK-Group Beta, a Zentalis Company
2 Previous Clinical Trials
484 Total Patients Enrolled